查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1575354

双标标靶治疗市场：按类型、应用、最终用户、给药途径、治疗机制分类 - 2025-2030 年全球预测

Dual Targeted Therapy Market by Type (Combination Therapy, Single Drug Therapy), Application (Autoimmune Diseases, Cardiovascular Diseases, Infectious Diseases), End User, Drug Administration Route, Therapy Mechanism - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 180 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

双标标靶治疗市场2023年估值为2.833亿美元，预计2024年将达到3.6128亿美元，复合年增长率为26.67%，预计到2030年将达到14.8283亿美元。

双标靶治疗是同时使用两种治疗药物，精确靶向疾病进展中涉及的多种途径，主要是肿瘤学和自体免疫疾病。与单一疗法相比，该策略旨在提高疗效、最大限度地减少抗药性并改善患者的治疗结果。对双标靶治疗的需求源于解决单途径抑制不足的复杂疾病的潜力，例如侵袭性癌症和多方面的自体免疫疾病，它将为该病症提供先进的治疗选择。这些治疗方法的应用涵盖癌症、心血管疾病和感染疾病，最终用途主要在医院、学术研究机构和生物技术公司。

主要市场统计
基准年[2023] 2.833 亿美元
预测年份 [2024] 36128万美元
预测年份 [2030] 1,482.83百万美元
复合年增长率（%） 26.67%

双标靶治疗市场受到慢性病的增加、生物技术的进步以及对疾病机制的更好理解等因素的影响。此外，有利的监管环境和研发方面的大量投资正在推动市场成长。医疗需求未满足的新兴市场存在潜在机会，製药公司和研究机构之间的伙伴关係可以促进管道开发。建议包括专注于个人化医疗方法和利用人工智慧技术来增强药物发现过程。

然而，它也存在局限性，包括高昂的开发成本、严格的监管核准以及复杂的药物交互作用可能产生的副作用。这些挑战需要全面的临床试验和强有力的上市后监测。此外，来自现有疗法和生物相似药的竞争是另一个挑战。儘管存在这些障碍，创新的成熟领域包括开发新型药物输送系统、探索协同效应组合方案以及针对需求未满足的罕见疾病。

双标靶治疗市场需要一种动态的方法，透过创新和策略联盟来推动成长并实现突破性治疗。鑑于这些治疗方法的复杂性，需要对研究和新技术进行持续投资，以克服当前的限制，抓住潜在的机会，并确保市场的持续扩张和成功。

市场动态：揭示快速发展的双标靶治疗市场的关键市场洞察

双标靶治疗市场正在因供需的动态交互作用而转变。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时也能帮助企业了解消费行为及其对製造业的影响。

  • 市场驱动因素
    • 加强生技公司和学术机构之间的合作，开发新型标靶治疗
    • 透过生物技术和基因组学的快速进步提高治疗药物的功效和安全性
    • 改善医疗基础设施并扩大新兴市场的准入范围将支持治疗方法的广泛使用
    • 增加监管支持以加速突破性治疗方法的核准流程
  • 市场限制因素
    • 双标靶疗法的高开发成本和资金筹措障碍
  • 市场机会
    • 罕见疾病和孤儿疾病双标靶治疗的开发
    • 拓展双标靶治疗在癌症领域的应用
    • 将人工智慧和机器学习整合到双标靶治疗的开发中
  • 市场挑战
    • 双标靶治疗的监管障碍和合规性问题

波特五力：驾驭双标靶治疗市场的策略工具

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势、解决弱点并避免潜在的挑战，以确保更强大的市场地位。

PESTLE分析：了解双标标靶治疗市场的外部影响

外部宏观环境因素在塑造双标靶治疗市场的绩效动态方面发挥关键作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解双标靶治疗市场的竞争格局

对双标靶治疗市场的详细市场占有率分析可以对供应商的业绩进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示自己的竞争定位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV定位矩阵双标靶治疗市场供应商绩效评估

FPNV定位矩阵是评估双标靶治疗市场供应商的关键工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析和建议描绘了双标靶治疗市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，对双标靶治疗市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：对当前市场环境的详细审查、主要企业的广泛资料、对其在市场中的影响力和整体影响力的评估。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点关注可望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 生技公司和学术机构之间不断加强合作，开发新的标靶治疗
      • 生物技术和基因组学的快速进步正在提高治疗方法的有效性和安全性
      • 扩大新兴市场的医疗基础设施和准入将推动治疗的采用
      • 增加监管支持以加速突破性治疗方法的核准流程
    • 抑制因素
      • 双标靶治疗的开发成本高且资金筹措障碍
    • 机会
      • 罕见病疑难病双标标靶治疗进展
      • 扩大双标靶治疗在肿瘤学的应用
      • 将人工智慧和机器学习整合到双标靶治疗的开发中
    • 任务
      • 双标靶治疗的监管障碍和合规性问题
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章双重标标靶治疗市场：依类型

  • 联合治疗
    • 生物製药组合
    • 低分子化合物与生物製药的组合
    • 低分子量化合物的组合
  • 单一疗法

第七章双重标标靶治疗市场：依应用分类

  • 自体免疫疾病
    • 多发性硬化症
    • 类风湿性关节炎
  • 心血管疾病
    • 冠状动脉疾病
    • 心臟衰竭
    • 高血压
  • 感染疾病
    • 细菌感染疾病
    • 病毒感染
  • 肿瘤学
    • 乳癌
    • 大肠直肠癌
    • 肺癌
    • 摄护腺癌

第八章双重标标靶治疗市场：依最终用户分类

  • 医院
  • 调查机构
  • 专科诊所

第九章依药品管理途径分類的双标靶治疗市场

  • 肌肉注射
  • 静脉
  • 口服
  • 皮下的

第十章 双标标靶治疗市场治疗机制

  • 免疫疗法
  • 标靶治疗

第十一章美洲双标标靶治疗市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十二章亚太双标标靶治疗市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十三章欧洲、中东和非洲双标标靶治疗市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第14章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议
Product Code: MRR-546E6FBB3647

The Dual Targeted Therapy Market was valued at USD 283.30 million in 2023, expected to reach USD 361.28 million in 2024, and is projected to grow at a CAGR of 26.67%, to USD 1,482.83 million by 2030.

Dual-targeted therapy involves the simultaneous use of two therapeutic agents that precisely target multiple pathways involved in disease progression, predominantly in oncology and autoimmune disorders. This strategy aims to enhance efficacy, minimize resistance, and improve patient outcomes compared to single-agent therapies. The necessity of dual-targeted therapy arises from its potential to address complex diseases where single-pathway inhibition is insufficient, thereby offering advanced treatment options for conditions like aggressive cancers or multifaceted autoimmune diseases. The application of these therapies extends into oncology, cardiovascular diseases, and infectious diseases, with end-use predominating in hospitals, academic research institutes, and biotechnology companies.

KEY MARKET STATISTICS
Base Year [2023] USD 283.30 million
Estimated Year [2024] USD 361.28 million
Forecast Year [2030] USD 1,482.83 million
CAGR (%) 26.67%

The market for dual-targeted therapy is influenced by factors such as increased prevalence of chronic diseases, advancements in biotechnology, and a growing understanding of disease mechanisms. Furthermore, favorable regulatory landscapes and substantial investments in R&D bolster market growth. Potential opportunities exist in emerging markets with unmet medical needs, and partnerships between pharmaceutical companies and research institutes can expedite pipeline development. Recommendations include focusing on personalized medicine approaches and leveraging AI technologies to enhance drug discovery processes.

However, limitations include high development costs, stringent regulatory approvals, and potential adverse reactions due to complex drug interactions. These challenges necessitate comprehensive clinical trials and robust post-marketing surveillance. Moreover, competition from existing therapies and biosimilars poses additional challenges. Despite these obstacles, areas ripe for innovation include the development of novel drug delivery systems, exploration of synergistic combination regimens, and targeting rare diseases with high unmet needs.

The dual-targeted therapy market demands a dynamic approach, where innovation and strategic alliances can drive growth and enable groundbreaking therapies. Given the intricate nature of these therapies, continuous investment in research and emerging technologies is essential to overcome current limitations and seize potential opportunities, thus ensuring sustained market expansion and success.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Dual Targeted Therapy Market

The Dual Targeted Therapy Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising collaborative efforts between biotech companies and academic institutions to develop novel targeted therapies
    • Rapid advancements in biotechnology and genomics enhancing the efficacy and safety profiles of therapies
    • Expansion of healthcare infrastructure and accessibility in emerging markets boosting therapy uptake
    • Increased regulatory support for fast-tracking the approval process of breakthrough therapies
  • Market Restraints
    • High development costs and financing barriers in dual-targeted therapy treatment
  • Market Opportunities
    • Development of dual targeted therapies for rare and orphan diseases
    • Expansion of dual targeted therapy applications in oncology
    • Integration of AI and machine learning in the development of dual targeted therapies
  • Market Challenges
    • Regulatory hurdles and compliance issues in dual-targeted therapy

Porter's Five Forces: A Strategic Tool for Navigating the Dual Targeted Therapy Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Dual Targeted Therapy Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Dual Targeted Therapy Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Dual Targeted Therapy Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Dual Targeted Therapy Market

A detailed market share analysis in the Dual Targeted Therapy Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Dual Targeted Therapy Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Dual Targeted Therapy Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Dual Targeted Therapy Market

A strategic analysis of the Dual Targeted Therapy Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Dual Targeted Therapy Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Amgen Inc., AstraZeneca PLC, Bayer AG, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Daiichi Sankyo Company, Limited, Eli Lilly and Company, Gilead Sciences, Inc., GlaxoSmithKline plc, Incyte Corporation, Johnson & Johnson, Merck & Co., Inc., Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals, Inc., Roche Holding AG, Sanofi S.A., Syndax Pharmaceuticals, Inc., and Takeda Pharmaceutical Company Limited.

Market Segmentation & Coverage

This research report categorizes the Dual Targeted Therapy Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Combination Therapy and Single Drug Therapy. The Combination Therapy is further studied across Biologic Combinations, Small Molecule and Biologic Combinations, and Small Molecule Combinations.
  • Based on Application, market is studied across Autoimmune Diseases, Cardiovascular Diseases, Infectious Diseases, and Oncology. The Autoimmune Diseases is further studied across Multiple Sclerosis and Rheumatoid Arthritis. The Cardiovascular Diseases is further studied across Coronary Artery Disease, Heart Failure, and Hypertension. The Infectious Diseases is further studied across Bacterial Infections and Viral Infections. The Oncology is further studied across Breast Cancer, Colorectal Cancer, Lung Cancer, and Prostate Cancer.
  • Based on End User, market is studied across Hospitals, Research Institutes, and Specialty Clinics.
  • Based on Drug Administration Route, market is studied across Intramuscular, Intravenous, Oral, and Subcutaneous.
  • Based on Therapy Mechanism, market is studied across Immunotherapy and Targeted Therapy.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising collaborative efforts between biotech companies and academic institutions to develop novel targeted therapies
      • 5.1.1.2. Rapid advancements in biotechnology and genomics enhancing the efficacy and safety profiles of therapies
      • 5.1.1.3. Expansion of healthcare infrastructure and accessibility in emerging markets boosting therapy uptake
      • 5.1.1.4. Increased regulatory support for fast-tracking the approval process of breakthrough therapies
    • 5.1.2. Restraints
      • 5.1.2.1. High development costs and financing barriers in dual-targeted therapy treatment
    • 5.1.3. Opportunities
      • 5.1.3.1. Development of dual targeted therapies for rare and orphan diseases
      • 5.1.3.2. Expansion of dual targeted therapy applications in oncology
      • 5.1.3.3. Integration of AI and machine learning in the development of dual targeted therapies
    • 5.1.4. Challenges
      • 5.1.4.1. Regulatory hurdles and compliance issues in dual-targeted therapy
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Dual Targeted Therapy Market, by Type

  • 6.1. Introduction
  • 6.2. Combination Therapy
    • 6.2.1. Biologic Combinations
    • 6.2.2. Small Molecule and Biologic Combinations
    • 6.2.3. Small Molecule Combinations
  • 6.3. Single Drug Therapy

7. Dual Targeted Therapy Market, by Application

  • 7.1. Introduction
  • 7.2. Autoimmune Diseases
    • 7.2.1. Multiple Sclerosis
    • 7.2.2. Rheumatoid Arthritis
  • 7.3. Cardiovascular Diseases
    • 7.3.1. Coronary Artery Disease
    • 7.3.2. Heart Failure
    • 7.3.3. Hypertension
  • 7.4. Infectious Diseases
    • 7.4.1. Bacterial Infections
    • 7.4.2. Viral Infections
  • 7.5. Oncology
    • 7.5.1. Breast Cancer
    • 7.5.2. Colorectal Cancer
    • 7.5.3. Lung Cancer
    • 7.5.4. Prostate Cancer

8. Dual Targeted Therapy Market, by End User

  • 8.1. Introduction
  • 8.2. Hospitals
  • 8.3. Research Institutes
  • 8.4. Specialty Clinics

9. Dual Targeted Therapy Market, by Drug Administration Route

  • 9.1. Introduction
  • 9.2. Intramuscular
  • 9.3. Intravenous
  • 9.4. Oral
  • 9.5. Subcutaneous

10. Dual Targeted Therapy Market, by Therapy Mechanism

  • 10.1. Introduction
  • 10.2. Immunotherapy
  • 10.3. Targeted Therapy

11. Americas Dual Targeted Therapy Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Dual Targeted Therapy Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Dual Targeted Therapy Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2023
  • 14.2. FPNV Positioning Matrix, 2023
  • 14.3. Competitive Scenario Analysis
  • 14.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. Amgen Inc.
  • 3. AstraZeneca PLC
  • 4. Bayer AG
  • 5. Boehringer Ingelheim International GmbH
  • 6. Bristol-Myers Squibb Company
  • 7. Daiichi Sankyo Company, Limited
  • 8. Eli Lilly and Company
  • 9. Gilead Sciences, Inc.
  • 10. GlaxoSmithKline plc
  • 11. Incyte Corporation
  • 12. Johnson & Johnson
  • 13. Merck & Co., Inc.
  • 14. Novartis AG
  • 15. Pfizer Inc.
  • 16. Regeneron Pharmaceuticals, Inc.
  • 17. Roche Holding AG
  • 18. Sanofi S.A.
  • 19. Syndax Pharmaceuticals, Inc.
  • 20. Takeda Pharmaceutical Company Limited

LIST OF FIGURES

  • FIGURE 1. DUAL TARGETED THERAPY MARKET RESEARCH PROCESS
  • FIGURE 2. DUAL TARGETED THERAPY MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY DRUG ADMINISTRATION ROUTE, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY DRUG ADMINISTRATION ROUTE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY THERAPY MECHANISM, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY THERAPY MECHANISM, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. AMERICAS DUAL TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. AMERICAS DUAL TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. UNITED STATES DUAL TARGETED THERAPY MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 19. UNITED STATES DUAL TARGETED THERAPY MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC DUAL TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. ASIA-PACIFIC DUAL TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA DUAL TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA DUAL TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. DUAL TARGETED THERAPY MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 25. DUAL TARGETED THERAPY MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. DUAL TARGETED THERAPY MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. DUAL TARGETED THERAPY MARKET DYNAMICS
  • TABLE 7. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY BIOLOGIC COMBINATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY SMALL MOLECULE AND BIOLOGIC COMBINATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY SMALL MOLECULE COMBINATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY SINGLE DRUG THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY MULTIPLE SCLEROSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY CORONARY ARTERY DISEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY HEART FAILURE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY HYPERTENSION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY BACTERIAL INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY VIRAL INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY DRUG ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
  • TABLE 39. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 40. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 41. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 42. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 43. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY THERAPY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 44. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 45. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 46. AMERICAS DUAL TARGETED THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 47. AMERICAS DUAL TARGETED THERAPY MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
  • TABLE 48. AMERICAS DUAL TARGETED THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 49. AMERICAS DUAL TARGETED THERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
  • TABLE 50. AMERICAS DUAL TARGETED THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
  • TABLE 51. AMERICAS DUAL TARGETED THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 52. AMERICAS DUAL TARGETED THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 53. AMERICAS DUAL TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 54. AMERICAS DUAL TARGETED THERAPY MARKET SIZE, BY DRUG ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
  • TABLE 55. AMERICAS DUAL TARGETED THERAPY MARKET SIZE, BY THERAPY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 56. AMERICAS DUAL TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 57. ARGENTINA DUAL TARGETED THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. ARGENTINA DUAL TARGETED THERAPY MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
  • TABLE 59. ARGENTINA DUAL TARGETED THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 60. ARGENTINA DUAL TARGETED THERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
  • TABLE 61. ARGENTINA DUAL TARGETED THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
  • TABLE 62. ARGENTINA DUAL TARGETED THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 63. ARGENTINA DUAL TARGETED THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 64. ARGENTINA DUAL TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 65. ARGENTINA DUAL TARGETED THERAPY MARKET SIZE, BY DRUG ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
  • TABLE 66. ARGENTINA DUAL TARGETED THERAPY MARKET SIZE, BY THERAPY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 67. BRAZIL DUAL TARGETED THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. BRAZIL DUAL TARGETED THERAPY MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
  • TABLE 69. BRAZIL DUAL TARGETED THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 70. BRAZIL DUAL TARGETED THERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
  • TABLE 71. BRAZIL DUAL TARGETED THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
  • TABLE 72. BRAZIL DUAL TARGETED THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 73. BRAZIL DUAL TARGETED THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 74. BRAZIL DUAL TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 75. BRAZIL DUAL TARGETED THERAPY MARKET SIZE, BY DRUG ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
  • TABLE 76. BRAZIL DUAL TARGETED THERAPY MARKET SIZE, BY THERAPY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 77. CANADA DUAL TARGETED THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. CANADA DUAL TARGETED THERAPY MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
  • TABLE 79. CANADA DUAL TARGETED THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 80. CANADA DUAL TARGETED THERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
  • TABLE 81. CANADA DUAL TARGETED THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
  • TABLE 82. CANADA DUAL TARGETED THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 83. CANADA DUAL TARGETED THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 84. CANADA DUAL TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 85. CANADA DUAL TARGETED THERAPY MARKET SIZE, BY DRUG ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
  • TABLE 86. CANADA DUAL TARGETED THERAPY MARKET SIZE, BY THERAPY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 87. MEXICO DUAL TARGETED THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. MEXICO DUAL TARGETED THERAPY MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
  • TABLE 89. MEXICO DUAL TARGETED THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 90. MEXICO DUAL TARGETED THERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
  • TABLE 91. MEXICO DUAL TARGETED THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
  • TABLE 92. MEXICO DUAL TARGETED THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 93. MEXICO DUAL TARGETED THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 94. MEXICO DUAL TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 95. MEXICO DUAL TARGETED THERAPY MARKET SIZE, BY DRUG ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
  • TABLE 96. MEXICO DUAL TARGETED THERAPY MARKET SIZE, BY THERAPY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 97. UNITED STATES DUAL TARGETED THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. UNITED STATES DUAL TARGETED THERAPY MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
  • TABLE 99. UNITED STATES DUAL TARGETED THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 100. UNITED STATES DUAL TARGETED THERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
  • TABLE 101. UNITED STATES DUAL TARGETED THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
  • TABLE 102. UNITED STATES DUAL TARGETED THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 103. UNITED STATES DUAL TARGETED THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 104. UNITED STATES DUAL TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 105. UNITED STATES DUAL TARGETED THERAPY MARKET SIZE, BY DRUG ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
  • TABLE 106. UNITED STATES DUAL TARGETED THERAPY MARKET SIZE, BY THERAPY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 107. UNITED STATES DUAL TARGETED THERAPY MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 108. ASIA-PACIFIC DUAL TARGETED THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 109. ASIA-PACIFIC DUAL TARGETED THERAPY MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
  • TABLE 110. ASIA-PACIFIC DUAL TARGETED THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 111. ASIA-PACIFIC DUAL TARGETED THERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
  • TABLE 112. ASIA-PACIFIC DUAL TARGETED THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
  • TABLE 113. ASIA-PACIFIC DUAL TARGETED THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 114. ASIA-PACIFIC DUAL TARGETED THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 115. ASIA-PACIFIC DUAL TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 116. ASIA-PACIFIC DUAL TARGETED THERAPY MARKET SIZE, BY DRUG ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
  • TABLE 117. ASIA-PACIFIC DUAL TARGETED THERAPY MARKET SIZE, BY THERAPY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 118. ASIA-PACIFIC DUAL TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 119. AUSTRALIA DUAL TARGETED THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 120. AUSTRALIA DUAL TARGETED THERAPY MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
  • TABLE 121. AUSTRALIA DUAL TARGETED THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 122. AUSTRALIA DUAL TARGETED THERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
  • TABLE 123. AUSTRALIA DUAL TARGETED THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
  • TABLE 124. AUSTRALIA DUAL TARGETED THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 125. AUSTRALIA DUAL TARGETED THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 126. AUSTRALIA DUAL TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 127. AUSTRALIA DUAL TARGETED THERAPY MARKET SIZE, BY DRUG ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
  • TABLE 128. AUSTRALIA DUAL TARGETED THERAPY MARKET SIZE, BY THERAPY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 129. CHINA DUAL TARGETED THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 130. CHINA DUAL TARGETED THERAPY MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
  • TABLE 131. CHINA DUAL TARGETED THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 132. CHINA DUAL TARGETED THERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
  • TABLE 133. CHINA DUAL TARGETED THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
  • TABLE 134. CHINA DUAL TARGETED THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 135. CHINA DUAL TARGETED THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 136. CHINA DUAL TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 137. CHINA DUAL TARGETED THERAPY MARKET SIZE, BY DRUG ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
  • TABLE 138. CHINA DUAL TARGETED THERAPY MARKET SIZE, BY THERAPY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 139. INDIA DUAL TARGETED THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 140. INDIA DUAL TARGETED THERAPY MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
  • TABLE 141. INDIA DUAL TARGETED THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 142. INDIA DUAL TARGETED THERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
  • TABLE 143. INDIA DUAL TARGETED THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
  • TABLE 144. INDIA DUAL TARGETED THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 145. INDIA DUAL TARGETED THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 146. INDIA DUAL TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 147. INDIA DUAL TARGETED THERAPY MARKET SIZE, BY DRUG ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
  • TABLE 148. INDIA DUAL TARGETED THERAPY MARKET SIZE, BY THERAPY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 149. INDONESIA DUAL TARGETED THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 150. INDONESIA DUAL TARGETED THERAPY MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
  • TABLE 151. INDONESIA DUAL TARGETED THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 152. INDONESIA DUAL TARGETED THERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
  • TABLE 153. INDONESIA DUAL TARGETED THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
  • TABLE 154. INDONESIA DUAL TARGETED THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 155. INDONESIA DUAL TARGETED THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 156. INDONESIA DUAL TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 157. INDONESIA DUAL TARGETED THERAPY MARKET SIZE, BY DRUG ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
  • TABLE 158. INDONESIA DUAL TARGETED THERAPY MARKET SIZE, BY THERAPY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 159. JAPAN DUAL TARGETED THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 160. JAPAN DUAL TARGETED THERAPY MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
  • TABLE 161. JAPAN DUAL TARGETED THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 162. JAPAN DUAL TARGETED THERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
  • TABLE 163. JAPAN DUAL TARGETED THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
  • TABLE 164. JAPAN DUAL TARGETED THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 165. JAPAN DUAL TARGETED THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 166. JAPAN DUAL TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 167. JAPAN DUAL TARGETED THERAPY MARKET SIZE, BY DRUG ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
  • TABLE 168. JAPAN DUAL TARGETED THERAPY MARKET SIZE, BY THERAPY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 169. MALAYSIA DUAL TARGETED THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 170. MALAYSIA DUAL TARGETED THERAPY MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
  • TABLE 171. MALAYSIA DUAL TARGETED THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 172. MALAYSIA DUAL TARGETED THERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
  • TABLE 173. MALAYSIA DUAL TARGETED THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
  • TABLE 174. MALAYSIA DUAL TARGETED THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 175. MALAYSIA DUAL TARGETED THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 176. MALAYSIA DUAL TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 177. MALAYSIA DUAL TARGETED THERAPY MARKET SIZE, BY DRUG ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
  • TABLE 178. MALAYSIA DUAL TARGETED THERAPY MARKET SIZE, BY THERAPY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 179. PHILIPPINES DUAL TARGETED THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 180. PHILIPPINES DUAL TARGETED THERAPY MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
  • TABLE 181. PHILIPPINES DUAL TARGETED THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 182. PHILIPPINES DUAL TARGETED THERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
  • TABLE 183. PHILIPPINES DUAL TARGETED THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
  • TABLE 184. PHILIPPINES DUAL TARGETED THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 185. PHILIPPINES DUAL TARGETED THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 186. PHILIPPINES DUAL TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 187. PHILIPPINES DUAL TARGETED THERAPY MARKET SIZE, BY DRUG ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
  • TABLE 188. PHILIPPINES DUAL TARGETED THERAPY MARKET SIZE, BY THERAPY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 189. SINGAPORE DUAL TARGETED THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 190. SINGAPORE DUAL TARGETED THERAPY MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
  • TABLE 191. SINGAPORE DUAL TARGETED THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 192. SINGAPORE DUAL TARGETED THERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
  • TABLE 193. SINGAPORE DUAL TARGETED THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
  • TABLE 194. SINGAPORE DUAL TARGETED THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 195. SINGAPORE DUAL TARGETED THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 196. SINGAPORE DUAL TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 197. SINGAPORE DUAL TARGETED THERAPY MARKET SIZE, BY DRUG ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
  • TABLE 198. SINGAPORE DUAL TARGETED THERAPY MARKET SIZE, BY THERAPY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 199. SOUTH KOREA DUAL TARGETED THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 200. SOUTH KOREA DUAL TARGETED THERAPY MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
  • TABLE 201. SOUTH KOREA DUAL TARGETED THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 202. SOUTH KOREA DUAL TARGETED THERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
  • TABLE 203. SOUTH KOREA DUAL TARGETED THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
  • TABLE 204. SOUTH KOREA DUAL TARGETED THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 205. SOUTH KOREA DUAL TARGETED THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 206. SOUTH KOREA DUAL TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 207. SOUTH KOREA DUAL TARGETED THERAPY MARKET SIZE, BY DRUG ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
  • TABLE 208. SOUTH KOREA DUAL TARGETED THERAPY MARKET SIZE, BY THERAPY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 209. TAIWAN DUAL TARGETED THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 210. TAIWAN DUAL TARGETED THERAPY MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
  • TABLE 211. TAIWAN DUAL TARGETED THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 212. TAIWAN DUAL TARGETED THERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
  • TABLE 213. TAIWAN DUAL TARGETED THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
  • TABLE 214. TAIWAN DUAL TARGETED THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 215. TAIWAN DUAL TARGETED THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 216. TAIWAN DUAL TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 217. TAIWAN DUAL TARGETED THERAPY MARKET SIZE, BY DRUG ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
  • TABLE 218. TAIWAN DUAL TARGETED THERAPY MARKET SIZE, BY THERAPY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 219. THAILAND DUAL TARGETED THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 220. THAILAND DUAL TARGETED THERAPY MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
  • TABLE 221. THAILAND DUAL TARGETED THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 222. THAILAND DUAL TARGETED THERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
  • TABLE 223. THAILAND DUAL TARGETED THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
  • TABLE 224. THAILAND DUAL TARGETED THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 225. THAILAND DUAL TARGETED THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 226. THAILAND DUAL TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 227. THAILAND DUAL TARGETED THERAPY MARKET SIZE, BY DRUG ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
  • TABLE 228. THAILAND DUAL TARGETED THERAPY MARKET SIZE, BY THERAPY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 229. VIETNAM DUAL TARGETED THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 230. VIETNAM DUAL TARGETED THERAPY MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
  • TABLE 231. VIETNAM DUAL TARGETED THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 232. VIETNAM DUAL TARGETED THERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
  • TABLE 233. VIETNAM DUAL TARGETED THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
  • TABLE 234. VIETNAM DUAL TARGETED THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 235. VIETNAM DUAL TARGETED THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 236. VIETNAM DUAL TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 237. VIETNAM DUAL TARGETED THERAPY MARKET SIZE, BY DRUG ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
  • TABLE 238. VIETNAM DUAL TARGETED THERAPY MARKET SIZE, BY THERAPY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 239. EUROPE, MIDDLE EAST & AFRICA DUAL TARGETED THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 240. EUROPE, MIDDLE EAST & AFRICA DUAL TARGETED THERAPY MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
  • TABLE 241. EUROPE, MIDDLE EAST & AFRICA DUAL TARGETED THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 242. EUROPE, MIDDLE EAST & AFRICA DUAL TARGETED THERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
  • TABLE 243. EUROPE, MIDDLE EAST & AFRICA DUAL TARGETED THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
  • TABLE 244. EUROPE, MIDDLE EAST & AFRICA DUAL TARGETED THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 245. EUROPE, MIDDLE EAST & AFRICA DUAL TARGETED THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 246. EUROPE, MIDDLE EAST & AFRICA DUAL TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 247. EUROPE, MIDDLE EAST & AFRICA DUAL TARGETED THERAPY MARKET SIZE, BY DRUG ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
  • TABLE 248. EUROPE, MIDDLE EAST & AFRICA DUAL TARGETED THERAPY MARKET SIZE, BY THERAPY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 249. EUROPE, MIDDLE EAST & AFRICA DUAL TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 250. DENMARK DUAL TARGETED THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 251. DENMARK DUAL TARGETED THERAPY MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
  • TABLE 252. DENMARK DUAL TARGETED THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 253. DENMARK DUAL TARGETED THERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
  • TABLE 254. DENMARK DUAL TARGETED THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
  • TABLE 255. DENMARK DUAL TARGETED THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 256. DENMARK DUAL TARGETED THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 257. DENMARK DUAL TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 258. DENMARK DUAL TARGETED THERAPY MARKET SIZE, BY DRUG ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
  • TABLE 259. DENMARK DUAL TARGETED THERAPY MARKET SIZE, BY THERAPY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 260. EGYPT DUAL TARGETED THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 261. EGYPT DUAL TARGETED THERAPY MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
  • TABLE 262. EGYPT DUAL TARGETED THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 263. EGYPT DUAL TARGETED THERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
  • TABLE 264. EGYPT DUAL TARGETED THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
  • TABLE 265. EGYPT DUAL TARGETED THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 266. EGYPT DUAL TARGETED THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 267. EGYPT DUAL TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 268. EGYPT DUAL TARGETED THERAPY MARKET SIZE, BY DRUG ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
  • TABLE 269. EGYPT DUAL TARGETED THERAPY MARKET SIZE, BY THERAPY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 270. FINLAND DUAL TARGETED THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 271. FINLAND DUAL TARGETED THERAPY MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
  • TABLE 272. FINLAND DUAL TARGETED THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 273. FINLAND DUAL TARGETED THERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
  • TABLE 274. FINLAND DUAL TARGETED THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
  • TABLE 275. FINLAND DUAL TARGETED THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 276. FINLAND DUAL TARGETED THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 277. FINLAND DUAL TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 278. FINLAND DUAL TARGETED THERAPY MARKET SIZE, BY DRUG ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
  • TABLE 279. FINLAND DUAL TARGETED THERAPY MARKET SIZE, BY THERAPY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 280. FRANCE DUAL TARGETED THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 281. FRANCE DUAL TARGETED THERAPY MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
  • TABLE 282. FRANCE DUAL TARGETED THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 283. FRANCE DUAL TARGETED THERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
  • TABLE 284. FRANCE DUAL TARGETED THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
  • TABLE 285. FRANCE DUAL TARGETED THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 286. FRANCE DUAL TARGETED THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 287. FRANCE DUAL TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 288. FRANCE DUAL TARGETED THERAPY MARKET SIZE, BY DRUG ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
  • TABLE 289. FRANCE DUAL TARGETED THERAPY MARKET SIZE, BY THERAPY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 290. GERMANY DUAL TARGETED THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 291. GERMANY DUAL TARGETED THERAPY MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
  • TABLE 292. GERMANY DUAL TARGETED THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 293. GERMANY DUAL TARGETED THERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
  • TABLE 294. GERMANY DUAL TARGETED THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
  • TABLE 295. GERMANY DUAL TARGETED THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 296. GERMANY DUAL TARGETED THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 297. GERMANY DUAL TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 298. GERMANY DUAL TARGETED THERAPY MARKET SIZE, BY DRUG ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
  • TABLE 299. GERMANY DUAL TARGETED THERAPY MARKET SIZE, BY THERAPY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 300. ISRAEL DUAL TARGETED THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 301. ISRAEL DUAL TARGETED THERAPY MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
  • TABLE 302. ISRAEL DUAL TARGETED THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 303. ISRAEL DUAL TARGETED THERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
  • TABLE 304. ISRAEL DUAL TARGETED THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
  • TABLE 305. ISRAEL DUAL TARGETED THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 306. ISRAEL DUAL TARGETED THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 307. ISRAEL DUAL TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 308. ISRAEL DUAL TARGETED THERAPY MARKET SIZE, BY DRUG ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
  • TABLE 309. ISRAEL DUAL TARGETED THERAPY MARKET SIZE, BY THERAPY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 310. ITALY DUAL TARGETED THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 311. ITALY DUAL TARGETED THERAPY MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
  • TABLE 312. ITALY DUAL TARGETED THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 313. ITALY DUAL TARGETED THERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
  • TABLE 314. ITALY DUAL TARGETED THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
  • TABLE 315. ITALY DUAL TARGETED THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 316. ITALY DUAL TARGETED THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 317. ITALY DUAL TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 318. ITALY DUAL TARGETED THERAPY MARKET SIZE, BY DRUG ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
  • TABLE 319. ITALY DUAL TARGETED THERAPY MARKET SIZE, BY THERAPY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 320. NETHERLANDS DUAL TARGETED THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 321. NETHERLANDS DUAL TARGETED THERAPY MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
  • TABLE 322. NETHERLANDS DUAL TARGETED THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 323. NETHERLANDS DUAL TARGETED THERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
  • TABLE 324. NETHERLANDS DUAL TARGETED THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
  • TABLE 325. NETHERLANDS DUAL TARGETED THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 326. NETHERLANDS DUAL TARGETED THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 327. NETHERLANDS DUAL TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 328. NETHERLANDS DUAL TARGETED THERAPY MARKET SIZE, BY DRUG ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
  • TABLE 329. NETHERLANDS DUAL TARGETED THERAPY MARKET SIZE, BY THERAPY MECHANISM, 2018-2030 (